

Early Breast Cancer Portfolio Updated 15/05/2024

Breast Ca type	Screening / During Diagnosis	Neo Adj / Window of Opportunity/ Pre Surgery	Surgical	Adjuvant	Loco- regional reccurrance	Follow-up
Mutation Specific	EMBRACE					Olympia
ER+ Her2-				Optima PRIMTIME AZ Cambria-1 [AZ Cambria-2]		Artemis PRIMETIME Neo-RT
Her2+				Astefania-HER2Radical		Persephone
TNBC		[IMpALA]		TROPION-Breast-3 SIV complete		Partner
Any	BRAID MyPeBs EMBED1&2	PBCP MIPA Narnia Mission Breast TRICKS [Neo-Taxis]	PBCP ATNEC Small	PARABLE	KORTUC	Quartus Fast Forward Import High Import Low POSNOC Add Aspirin
DCIS						

Closed to recruitment, pts in follow up

[Trials in set up]



Early Br Ca Trial information and links

Trial	Description
Add Aspirin	Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and
·	Survival After Primary Therapy in Common Non Metastatic Solid Tumours - Full Text
	<u>View - ClinicalTrials.gov</u>
Astefania	A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and
	Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High
	Risk of Recurrence Following Preoperative Therapy - Full Text View -
	<u>ClinicalTrials.gov</u>
ATNEC	Axillary Management in Breast Cancer Patients With Needle Biopsy Proven Nodal
	Metastases After Neoadjuvant Chemotherapy - Full Text View - ClinicalTrials.gov
AZ Cambria 1	Study Details A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at
	<u>Least 2 Years of Standard Adjuvant Endocrine Therapy ClinicalTrials.gov</u>
AZ Cambria 2	An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in
TD101/0	ER+/HER2- Early Breast Cancer (CAMBRIA-2) - Full Text View - ClinicalTrials.gov
Breast TRICKS	Imaging Vascularity in Primary Breast Cancer with Novel MRI Techniques
BRAID	Breast Screening - Risk Adaptive Imaging for Density - Full Text View -
	<u>ClinicalTrials.gov</u>
Compulse	Comparison Trial of Open-tip Pulsed Needle Biopsy and Conventional Core Biopsy in
	Axillary Lymph Nodes (COMPULSE)
EMBED1&2	Early Markers for Breast Cancer Detection (cam.ac.uk)
EMBRACE	EMBRACE Study - Centre for Cancer Genetic Epidemiology (cam.ac.uk)
HER2Radical	HER2-RADICAL study (Response ADaptive CAre plan) - tailoring treatment for HER2-
	positive (HER2+) early breast cancer. Patients with HER2+ early breast cancer who
	have recently completed standard of care (SoC) non-anthracycline-containing
	neoadjuvant systemic anti-cancer therapy (neoSACT) with pathological complete
10.4 0.1.0	response (pCR; ypT0/Tis ypN0 M0).
IMpALA	A Proof of Concept, Window Trial of the IMmunological Effects of AveLumab and
N. DT	Aspirin in Triple-Negative Breast Cancer (IMpALA)
NeoRT	Neo-RT: A Study Investigating Whether Changing the Sequence of Treatments
	(Starting Radiotherapy Followed by Hormone Therapy Before Surgery) is Feasible -
Louis	Full Text View - ClinicalTrials.gov
Loris	LORIS - University of Birmingham A Phase III Trial of Surgery versus Active
	Monitoring for Low Risk Ductal Carcinoma in Situ (DCIS) (CLOSED March 2020; no
MIAMI	follow up) MIAMI Safe Surgery for Multiple Breast Cancers - Full Text View - ClinicalTrials.gov
MyPeBs	My Personalized Breast Screening - Full Text View - ClinicalTrials.gov
NARNIA	Sodium (23Na) MRI for Tumour Characterisation and Assessment of Therapy
	Response in Breast Cancer - Full Text View - ClinicalTrials.gov
Optima	OPTIMA (optimabreaststudy.com) Optimal Personalised Treatment of early breast
	cancer using Multi-parameter Analysis



PARABLE	Proton beam therapy in patients with breast cancer: evaluating early and late effects		
Partner /	Platinum and Polyadenosine 5'Diphosphoribose Polymerisation (PARP) Inhibitor for		
Partnering	Neoadjuvant Treatment of Triple Negative Breast Cancer (TNBC) and/or Germline		
	BRCA (gBRCA) Positive Breast Cancer - Full Text View - ClinicalTrials.gov		
РВСР	Personalised Breast Cancer Program		
Pioneer	A Pre-operative Window Study of Letrozole Plus PR Agonist (Megestrol Acetate)		
	Versus Letrozole Alone in Post-menopausal Patients With ER-positive Breast Cancer -		
	Full Text View - ClinicalTrials.gov COMPLETED NOV 2022		
POSNOC	POSNOC - A Trial Looking at Axillary Treatment in Early Breast Cancer - Full Text View		
	- ClinicalTrials.gov		
Primetime	PRIMETIME - The Institute of Cancer Research, London (icr.ac.uk) Post-operative		
	avoidance of radiotherapy: biomarker selection of women categorised to be in a		
	very low risk group by IHC4+C.		
Small	The SMALL study for treating early-stage breast cancer NCRI		
TROPION-	A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of		
Breast03	Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without		
	Pathological Complete Response Following Neoadjuvant Therapy (TROPION-		
	Breast03) - Full Text View - ClinicalTrials.gov		



Advanced & Metastatic Breast Cancer Portfolio

Breast Ca type	Locally Advanced	Metastatic 1 st line	Metastatic 2 nd line	Metastatic 3 rd line +		
Tumour DNA Seq + Molecular			Anti-PDL-1	Atezolizumab		
Therapy (Basket			[FGFF	Inhibitor]		
of Baskets			[MET	[Inhibitor]		
ER+ Her2-	FAIM	Serena 4 – oral SERD	Serena	1 - Oral SERD		
		Serena 6 – ora	I SERD			
		FAIM	[Poseido	on 2 – Lobular]		
Her2 Low			Destiny Brea	st -06 – in follow up		
Her2			Destiny Brea	st -07 – in follow up		
TNBC		Begonia				
		Petra				
			[Novel Immunother	apy: ICOS Inhibitor KY1044]		
New Drug + radiotherapy						
Any	KORTUC					
	РВСР					
		DETECT (recruitment on hold)				

[Trials in set up]



Advanced Br Ca Trial information and links

Trial	Description	
Begonia	A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer - Full Text View - ClinicalTrials.gov	
ВоВ	A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets) - Full Text View - ClinicalTrials.gov	
Calibrate	Cambridge Liquid Biopsy and Tumour Profiling Study for Patients on Experimental Therapeutics Trials - Full Text View - ClinicalTrials.gov	
Destiny06	Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer - Full Text View - ClinicalTrials.gov	
Destiny07	A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer - Full Text View - ClinicalTrials.gov	
DETECT	A study looking at cancer cells and a substance called nucleic acid in the bloodstreams of women with breast cancer that has spread to other parts of the body (Detect) Cancer Research UK	
Her2Climb02	A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer - Full Text View - ClinicalTrials.gov	
[FAIM]	Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression - Full Text View - ClinicalTrials.gov	
KORTUC	KORTUC Phase II - Intra-tumoural Radiation Sensitizer in Patients With Locally Advanced/Recurrent Breast Cancer - Full Text View - ClinicalTrials.gov	
[KY1044]	Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer - Full Text View - ClinicalTrials.gov	
Patriot	Phase I Study to Assess Safety of AZD6738 Alone and in Combination With Radiotherapy in Patients With Solid Tumours - Full Text View - ClinicalTrials.gov	
PBCP	Personalised Breast Cancer Program	
[PETRA]	Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies - Full Text View - ClinicalTrials.gov	
Serena1	Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer - Full Text View - ClinicalTrials.gov	
Serena4	A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease Full Text View - ClinicalTrials.gov	
Serena6	Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) - Full Text View - ClinicalTrials.gov	